Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of renal allograft with current actinic keratosis I or II or successfully treated actinic keratosis III (inclusion possible immediately after completed wound healing from surgical excision), invasive squamous cell carcinoma (SCC), basal cell carcinoma and/or premalignant neoplastic skin lesions~* Age 18 years and older~* Minimum period of 6 month after renal transplantation~* Stable renal function and a calculated creatinine clearance of at least 40 ml/min~* Written informed consent~* Proteinuria ≤ 800 mg/d at time of enrolment~* Successfully treated solid tumor (no recurrence or metastasis in the last 2 years)~Exclusion Criteria:~* Current Sirolimus- or Everolimus- intake~* Instable graft function (creatinine clearance \< 40 ml/min)~* Graft rejection within the 3 previous months~* Proteinuria \> 800 mg/d~* Non-controlled hyperlipidemia (Cholesterol \>7,8 mmol/l, Triglycerides \> 4)~* Leucopenia \< 2500/nl~* Thrombocytopenia \< 90/nl~* Pregnancy or breastfeeding~* Women of childbearing age without highly effective contraception (= defined as those which result in a low failure rate (i.e. less than 1 % per year))~* Known allergy to macrolides~* Current participation in other studies~* Refusal to sign informed consent form~* Neoplasm other than defined as inclusion criteria~* All contraindications to SRL (see package insert, appendix)~* Persons who are detained officially or legally to an official institute

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
- 2 (Type: ACTIVE_COMPARATOR): Patients will stay on their previous immunosuppressive regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).